Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.

Abstract

We present a 65-year-old woman who developed a diffuse pruritic papular eruption after receiving induction chemotherapy with daunorubicin and cytarabine for newly diagnosed acute myelomonocytic leukemia. The rash improved clinically with triamcinolone treatment and chemotherapy was allowed to continue. This case adds to the growing literature of transient acantholytic dermatosis development in the setting of anti-cancer therapy and emphasizes the importance of clinicopathologic correlation in cutaneous eruptions in cancer patients.

• Authors: Elanee Simmons, Soraya Foutouhi, Danielle M Tartar, Maija Kiuru
• Journal: Dermatology online journal (Dermatol Online J) Vol. 28 Issue 3 (Jun 15 2022) ISSN: 1087-2108 [Electronic] United States
• PMID: 36259808 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cytarabine
• Daunorubicin
• Triamcinolone

Topics

• Female
• Humans
• Child
• Aged
• Cytarabine
• Daunorubicin (adverse effects)
• Induction Chemotherapy (adverse effects)
• Leukemia, Myeloid, Acute (drug therapy)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Exanthema
• Pruritus (drug therapy)
• Triamcinolone (therapeutic use)